Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

Abstract The heat shock protein 90 inhibitor, luminespib, has demonstrated potent preclinical activity against numerous cancers. However, clinical translation has been impeded by dose-limiting toxicities that have necessitated dosing schedules which have reduced therapeutic efficacy. As such, lumine...

Full description

Bibliographic Details
Main Authors: Brittany Epp-Ducharme, Michael Dunne, Linyu Fan, James C. Evans, Lubabah Ahmed, Pauric Bannigan, Christine Allen
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-90585-w